Award

Ask AI about this notice

Summarise, research or assess it with AI

View Markdown

Share this notice

Send this contract to a colleague

RMH clonoSEQ(r) Assay

The Royal Marsden NHS Foundation Trust

This public procurement record has 2 releases in its history.

Award

30 Dec 2025 at 11:11

UK6 - Contract Award Notice
Award

22 Dec 2025 at 10:38

UK5 - Transparency Notice
Summary of the contracting process

The Royal Marsden NHS Foundation Trust has concluded a procurement process for the "RMH clonoSEQ® Assay," focusing on the detection and monitoring of minimal residual disease (MRD) in haematologic malignancies. The procurement, facilitated via a direct award to Adaptive Biotechnologies Corporation, has been completed, with the contract scheduled to run from 20th January 2026 to 19th January 2031. The project addresses the medical industry category and takes place in London, UK, serviced under the central government's classification. The procurement process, driven by the unique capabilities and intellectual property owned by the supplier, was finalised on 22nd December 2025, with a total contract value of GBP 1,389,850. Key procurement stages include tender initiation and contract awarding.

This tender represents substantial opportunities for businesses involved in the provision of next-generation sequencing-based tests, software platforms, and associated technical support. Companies that specialise in laboratory reagents, particularly those with experience in complying with clinical guidelines and regulatory standards, are well-positioned to gain from similar contracts. The requirement for ongoing technical support, comprehensive delivery schedules, and integration with existing health systems opens avenues for both large-scale enterprises and SMEs focusing on healthcare diagnostics and biotechnologies. By engaging in such specialised contracts, businesses have the potential to enhance their market presence and contribute to advancements in medical diagnostics.

How relevant is this notice?

Notice Information

Notice Title

RMH clonoSEQ(r) Assay

Notice Description

The procurement of a next-generation sequencing (NGS)-based test assay designed for the detection and monitoring of minimal residual disease (MRD) in patients with certain haematologic malignancies, such as multiple myeloma, acute lymphoblastic leukaemia (ALL), and chronic lymphocytic leukaemia (CLL). The required goods and services include: * Provision of assay kits and reagents suitable for the intended patient population. * Use of a software platform for analysis and reporting of results. * Training and technical support for laboratory and clinical staff to ensure accurate sample processing, data interpretation, and integration into clinical workflows. * Ongoing technical support, maintenance, and updates for both hardware (if applicable) and software components. * Delivery of consumables and reagents on a schedule that aligns with clinical demand, ensuring continuity of patient testing. * Compliance with all relevant regulatory standards (e.g., CE-IVD, UKCA marking) and data protection requirements for patient information. * Optional: Integration with existing laboratory information management systems (LIMS) and electronic health records (EHR), if required. * MRD sensitivity threshold of 10-5 or lower * Must work on DNA * Performance data must be supported by evidence generated in relevant disease specific Clinical Trials * Recognised technology included in clinical guidelines * Ability to track clonal evolution

Procurement Information

The supplier owns the IP for this assay. The unique factors are detailed below: Unique Capabilities: * Sensitivity: clonoSEQ can detect MRD down to one cancer cell among a million healthy cells, deeper than flow cytometry or PCR. This level of sensitivity is critical for accurately assessing MRD in patients for both depth of response and early relapse detection. * Standardization: clonoSEQ is a sole-source test. All reagents, materials, and equipment are needed to perform the assay. * FDA Approval: clonoSEQ is the first and only FDA-cleared assay for MRD detection ALL, CLL or MM. * Comprehensive Data Analysis: The assay includes sophisticated bioinformatics tools that offer detailed insights into clonal evolution and disease progression, which are not available with other MRD testing methods, resulting in a tracking report of disease burden over time. * Clinical Guidelines: NGS MRD assessment is included in clinical guidelines for ALL, CLL, DLBCL, and multiple myeloma. Monitoring MRD is crucial for assessing the treatment effectiveness and early detection of relapse in patients with lymphoid malignancies, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), diffuse large b-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and multiple myeloma (MM). Traditional methods, such as flow cytometry and polymerase chain reaction (PCR), lack the sensitivity and standardisation required for consistent and deep MRD detection across different laboratories and clinical settings. The clonoSEQ Assay was developed by Adaptive Biotechnologies in accordance with CLIA/College of American Pathologists (CAP) requirements. Adaptive Biotechnologies is a single-source provider of the clonoSEQ Assay and therefore is uniquely positioned to meet the MRD detection needs for patients.

Notice Details

Publication & Lifecycle

Open Contracting ID
ocds-h6vhtk-05fb40
Publication Source
Find A Tender Service
Latest Notice
https://www.find-tender.service.gov.uk/Notice/086403-2025
Current Stage
Award
All Stages
Award

Procurement Classification

Notice Type
UK6 - Contract Award Notice
Procurement Type
Standard
Procurement Category
Goods
Procurement Method
Direct
Procurement Method Details
Direct award
Tender Suitability
SME, VCSE
Awardee Scale
SME

Common Procurement Vocabulary (CPV)

CPV Divisions

33 - Medical equipments, pharmaceuticals and personal care products

CPV Codes

33696500 - Laboratory reagents

Notice Value(s)

Tender Value
Not specified
Lots Value
Not specified
Awards Value
£1,158,208 £1M-£10M
Contracts Value
Not specified

Notice Dates

Publication Date
30 Dec 20257 months ago
Submission Deadline
Not specified
Future Notice Date
Not specified
Award Date
22 Dec 20258 months ago
Contract Period
20 Jan 2026 - 19 Jan 2031 Over 5 years
Recurrence
Not specified

Notice Status

Tender Status
Complete
Lots Status
Complete
Awards Status
Pending
Contracts Status
Not Specified

Buyer & Supplier

Contracting Authority (Buyer)

Main Buyer
The Royal Marsden NHS Foundation Trust
Contact Name
Available with D3 Tenders Premium →
Contact Email
Available with D3 Tenders Premium →
Contact Phone
Available with D3 Tenders Premium →

Buyer Location

Locality
LONDON
Postcode
SW3 6JJ
Postcode Area
South West London
Country
England
Major Region (ITL 1)
TLI London
Basic Region (ITL 2)
TLI3 Inner London - West
Small Region (ITL 3)
TLI33 Kensington & Chelsea and Hammersmith & Fulham
Delivery Location
Not specified
Local Authority
Kensington and Chelsea
Electoral Ward
Stanley
Westminster Constituency
Chelsea and Fulham

Supplier Information

Number of Suppliers
1
Supplier Name

Adaptive Biotechnologies Corporation

Further Information

Notice Documents

Open Contracting Data Standard (OCDS)

View full OCDS Record for this contracting process

JSON Markdown

The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.

Loading OCDS record...